Exxonmobil Investment Management Inc. TX reduced its stake in shares of Humana Inc. (NYSE:HUM) by 16.4% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 27,708 shares of the insurance provider’s stock after selling 5,452 shares during the period. Exxonmobil Investment Management Inc. TX’s holdings in Humana were worth $6,667,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in HUM. Guardian Life Insurance Co. of America increased its stake in shares of Humana by 0.7% in the first quarter. Guardian Life Insurance Co. of America now owns 575 shares of the insurance provider’s stock valued at $119,000 after buying an additional 4 shares during the period. Creative Planning increased its stake in shares of Humana by 0.3% in the second quarter. Creative Planning now owns 4,874 shares of the insurance provider’s stock valued at $1,173,000 after buying an additional 15 shares during the period. AE Wealth Management LLC increased its stake in shares of Humana by 3.8% in the first quarter. AE Wealth Management LLC now owns 1,305 shares of the insurance provider’s stock valued at $269,000 after buying an additional 48 shares during the period. Howard Hughes Medical Institute increased its stake in shares of Humana by 6.2% in the first quarter. Howard Hughes Medical Institute now owns 1,178 shares of the insurance provider’s stock valued at $243,000 after buying an additional 69 shares during the period. Finally, Financial Advisors Network Inc. increased its stake in shares of Humana by 6.1% in the first quarter. Financial Advisors Network Inc. now owns 1,367 shares of the insurance provider’s stock valued at $316,000 after buying an additional 79 shares during the period. 99.62% of the stock is currently owned by institutional investors.

Shares of Humana Inc. (HUM) opened at 245.93 on Monday. The stock has a 50 day moving average of $236.19 and a 200 day moving average of $220.68. Humana Inc. has a 52-week low of $163.50 and a 52-week high of $251.79. The firm has a market cap of $35.54 billion, a price-to-earnings ratio of 20.23 and a beta of 0.91.

Humana (NYSE:HUM) last posted its earnings results on Wednesday, August 2nd. The insurance provider reported $3.49 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $3.08 by $0.41. The firm had revenue of $13.53 billion during the quarter, compared to analysts’ expectations of $13.61 billion. Humana had a net margin of 3.37% and a return on equity of 15.85%. During the same period in the previous year, the company earned $2.30 earnings per share. Equities analysts predict that Humana Inc. will post $11.40 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Exxonmobil Investment Management Inc. TX Cuts Stake in Humana Inc. (NYSE:HUM)” was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece of content on another publication, it was stolen and republished in violation of U.S. and international copyright law. The original version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/08/07/humana-inc-nysehum-shares-sold-by-exxonmobil-investment-management-inc-tx-updated-updated-updated.html.

Several brokerages have issued reports on HUM. Cowen and Company reaffirmed an “outperform” rating and issued a $230.00 price target on shares of Humana in a report on Tuesday, April 25th. Leerink Swann upped their price objective on shares of Humana from $250.00 to $265.00 and gave the company an “outperform” rating in a research note on Tuesday, May 30th. Zacks Investment Research raised shares of Humana from a “hold” rating to a “buy” rating and set a $257.00 price objective on the stock in a research note on Thursday, May 25th. BidaskClub downgraded shares of Humana from a “buy” rating to a “hold” rating in a research note on Tuesday, June 13th. Finally, UBS AG reissued a “neutral” rating and set a $237.00 price objective (up previously from $205.00) on shares of Humana in a research note on Wednesday, June 28th. Two analysts have rated the stock with a sell rating, eight have given a hold rating and twelve have given a buy rating to the stock. Humana has a consensus rating of “Hold” and an average target price of $241.65.

In other news, VP Heidi S. Margulis sold 1,500 shares of Humana stock in a transaction that occurred on Friday, May 26th. The shares were sold at an average price of $231.96, for a total value of $347,940.00. Following the transaction, the vice president now owns 8,150 shares of the company’s stock, valued at $1,890,474. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, SVP Brian P. Leclaire sold 4,971 shares of Humana stock in a transaction that occurred on Wednesday, June 28th. The shares were sold at an average price of $240.00, for a total transaction of $1,193,040.00. Following the completion of the transaction, the senior vice president now directly owns 14,258 shares in the company, valued at approximately $3,421,920. The disclosure for this sale can be found here. 0.80% of the stock is owned by insiders.

Humana Company Profile

Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.

Institutional Ownership by Quarter for Humana (NYSE:HUM)

Receive News & Stock Ratings for Humana Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana Inc. and related stocks with our FREE daily email newsletter.